n INTRODUCTION T umor necrosis factor alpha (TNFα) antagonists showed their efficacy and safety in controlling disease signs and symptoms of ankylosing spondylitis (AS) (1) . The concept of disease remission plays a relevant role in the management of AS, representing a major treatment target that should consider different aspects of the disease, including extra-articular manifestations, i.e. psoriasis, inflammatory bowel disease (IBD), uveitis, and acute phase reactants (2) . Owing to the lack of definition of the differentiation between complete clinical remission and a status of The objective of this study was to evaluate the predictive factors for achieving partial remission (PR) in patients with ankylosing spondylitis (AS) treated with anti-TNFα. We longitudinally enrolled in a multi-center study 214 AS patients, classified according to New York criteria, treated with anti-TNFα drugs adalimumab (ADA), etanercept (ETA) and infliximab (INF) with at least 12 months of follow up. PR was reached when the score was <20 mm (on a visual analogue scale of 0-100 mm) in each of the following 4 domains: 1) patient global assessment (in the last week); 2) pain (spinal pain); 3) function [measured by the bath ankylosing spondylitis functional index (BASFI)]; 4) inflammation [mean of intensity and duration of morning stiffness, from the bath ankylosing spondylitis disease activity index (BASDAI)]. Two hundred fourteen AS patients (M/F=160/54; median age/range=43.2/19-78 years; median disease duration/range=96/36-189 months) were treated with ADA (15.8%), ETA (28.9%) and INF (55.1%). At 12 and 24 months, high serum level of C reactive protein (CRP) (≥2 vs ≤0.8 mg/dL) were associated with higher rate of PR in AS patients treated with anti-TNFα drugs. At 24 months, PR was associated with shorter disease duration (≤36 vs ≥189 months) and higher erythrosedimentation rate (ESR) values (≥45 vs ≤17 mm/h). In male patients lower bath ankylosing spondylitis metrology index (BASMI) (≤2 vs ≥6) and absence of psoriasis were associated with higher PR rate only at 12 months. Other parameters assessed before treatment, such as BASDAI, BAS-FI, peripheral arthritis, inflammatory bowel disease and uveitis were not associated with PR. Our long-term longitudinal study in a setting of clinical practice showed that inflammatory parameters (i.e. CRP, ESR) and disease duration represent the most important predictive variables to achieve PR with an anti-TNFα treatment. (11) (12) (13) (14) . The aim of this study was to evaluate the predictive factors for achieving PR in a large cohort of AS patients treated with adalimumab (ADA), etanercept (ETA) and infliximab (INF) in a real-life clinical setting.
n MATERIALS AND METHODS
A longitudinal observational study was performed in 6 secondary referral rheumatologic Italian centers (Roma, Campobasso, Milano, Padova, Potenza and Reggio Emilia). We studied 214 AS patients, classified according to New York criteria (15) , treated with TNFα antagonist with a follow-up period ranging from 12 to 24 months. ADA (40 mg every two weeks) and ETA (25 mg twice a week or 50 mg once a week) were administered subcutaneously; INF was administered intravenously at 3-5 mg/kg at 0-2-6 weeks, then every 6-8 weeks. All patients signed an informed consent according to the Declaration of Helsinki and the design of the study was approved by the local ethical committee (La Sapienza University of Rome). At the beginning of the anti-TNFα treatment, the main demographic, clinical, laboratory and radiological characteristics of each AS patients, including gender, age, disease duration, clinical pattern (axial with or without peripheral arthritis), extra-articular manifestations (i.e. psoriasis, IBD, uveitis), HLA-B27 typing and X-ray sacroiliitis grade according to the New York criteria (15) were collected. Bath ankylosing spondylitis metrology index (BASMI) (16) , Bath ankylosing spondylitis disease activity index (BASDAI) (17) , BASFI (18) , the patient's visual analogue scale (VAS) of 0-100 mm on disease activity and overall spinal pain, the number of tender and swollen joints, and laboratory parameters such as erythrosedimentation rate (ESR) and CRP were evaluated at baseline and after 12 and 24 months from anti-TNFα treatment initiation. PR was reached when the score was <20 mm (on a VAS of 0-100 mm) in each of the following 4 domains: 1) patient global assessment (in the last week); 2) pain (spinal pain); 3) function (measured by the BASFI); inflammation (mean of intensity and duration of morning stiffness, from the BASDAI) (2, 19) . The association of PR with the main variables at baseline was studied. In particular, continuous variables (i.e. age, disease duration, CRP, ESR, BASDAI, BASMI, BASFI) were analyzed by comparing the different quartiles. All anti-rheumatic treatments, including disease modifying anti-rheumatic drugs (DMARDs), steroids, non-steroidal antiinflammatory drugs (NSAIDs) and comorbidities were recorded. The reasons for discontinuation were classified as lack of efficacy, adverse event, or other reasons. The definition of lack of effectiveness was based on a clinical evaluation according to ASAS/European League Against Rheumatism (EULAR) recommendations for the management of AS (20) .
Statistical analysis
Categorical variables were analyzed using the χ-square test with Yates correction or the Fisher exact test. Association of predictor variables with ASAS partial remission was explored using an odds ratio (OR) with a 95% confidence interval (CI). OR was interpreted as: 1.5 to 1 weak association; 2.5 to 1 moderate association; 4 to 1 strong association and 10 to 1 very strong 
n RESULTS
The main demographic, clinical and laboratory features of AS patients (n=214) treated with TNFα blockers (ADA=34, ETA=62, INF=118) at baseline are shown in Table I . Among the 214 patients, the anti-TNFα treatment was still administered to 203 (94.8%) at 12 months and to 158 (73.9%) at 24 months. During the follow up, the overall rate of discontinuation of anti-TNFα drug was 9.3% (n=20), including 11 patients (5.1%) who stopped the drug due to loss of effectiveness, 5 (2.3%) patients due to adverse events and 4 (1.8%) for other reasons. ADA, ETA, and INF were discontinued due to loss of effectiveness in 4 (1.8%), 1 (0.4%) and in 6 (2.8%), patients respectively. PR rates at 12 and 24 months during treatment with ADA, ETA and INF in patients with AS are shown in Figure 1 . The PR rate was not significantly different among all anti-TNF-α (ADA, ETA or INF). During the two-year study, 131 (61.2%) patients reached PR. In particular, 113 (86.2%) patients reached PR within 12 months from the beginning of the anti-TNFα therapy. The association of a PR response with the main variables at baseline in AS treated with ADA, ETA and INF at 12 and 24 months of follow up is shown in Table II . In particular, the continuous variables (i.e. age, disease duration, CRP, ESR, BASDAI, BASMI, BASFI) were analyzed by comparing the different quartiles (Table II) . At 12 and 24 months, high serum levels of CRP (≥2 vs ≤0.8 mg/dL), were associated with a higher PR rate in AS patients treated with anti-TNFα drugs. At 24 months, PR was associated with shorter disease duration (≤36 vs ≥189 months) and higher ESR values (≥45 vs ≤17 mm/h). Male sex, lower BASMI (≤2 vs ≥6) and absence of psoriasis were associated with higher PR rate only at Our experience in a clinical practice setting, confirmed previous results that high serum level of CRP were associated with a higher rate of PR in AS patients treated with anti-TNFα drugs (14) . In fact, ASSERT and GO-RAISE trial data were analyzed to identify baseline predictors for various disease-state and disease-activity outcome instruments in AS (14) . In this study CRP, together with age, BASFI score, enthesitis, therapy and HLA-B27 genotype, was identified as a predictor variable with selected outcome instruments, including ASAS PR at six months (14) . These results are in keeping with other studies showing that CRP was associated to BASDAI 50 response (12, 21) . Moreover, in our study the evidence that high ESR (≥45 mm/h) had a predictive value supports that this inflammation parameter could be considered an alternative in cases where CRP is not available, according to the use of AS disease activity score (ASDAS) with CRP or ESR (22) . The strong association of short disease duration (≤36 months) with PR confirmed the results of Rudwaleit et al., who analyzed factors associated to clinical response BASDAI 50 in two clinical trials on ETA and INF (21) . This association could be an important issue in order to suggest an early treatment intervention. Furthermore, in our study we found that patients with lower BASMI (≤2) before starting an anti-TNFα therapy had a higher PR rate compared with patients with higher BASMI score (≥6). This metrology parameter, even in the absence of inflammatory activity, could influence the domains of PR, such as BASFI and the patient global assessment, reducing the probability of achieving a remission status. In our study, the presence of grade IV sacroiliitis did not affect the PR rate. These results suggest that the TNFα treatment could be useful also in patients with severe axial involvement according to the efficacy of ADA in AS patients with a total spine ankylosis (23) . Female sex is considered a risk factor for functional disability, but its predictive value for clinical response to anti-TNFα in AS has not been reported (24) . In our study a weak evidence of association of male gender with PR was demonstrated only at 12 months. In our study, other baseline variables (i.e. age, HLA-B27, BASDAI, BASFI and peripheral involvement) did not affect the PR rate. The weak association of BAS-DAI with PR could be due to the inclusion criteria giving a homogeneous selection of patients based on elevated BASDAI scores. Among extra-articular manifestations, the predictive value of psoriasis with a good clinical response to anti-TNFα drugs is still debated (5, 24, 25) . In our experience, the presence of psoriasis at baseline evaluation was associated with a lower PR rate after 12 months of anti-TNFα therapy. Some discrepancies of our results with previous studies can be explained by a different definition of cut-off levels of putative predictive variables, different outcome measures, study designs and follow-up periods.
In particular, it has to be emphasized that observational studies might yield different findings from those coming from randomized controlled trials. A limitation of this study was the lack of magnetic resonance imaging (MRI) of sacroiliac joints and spine, but in our experience, based on clinical practice, the availability of MRI was not mandatory for recruitment. MRI is actually the cornerstone of the classification of non-radiographic axial spondyloartritis and some studies showed the ability of anti-TNFα to reduce the presence and extension of the inflammatory lesion on MRI. Furthermore, other experience demonstrated the predictive value of bone marrow edema to achieve clinical response to anti-TNFα both in patients with SA and non-radiographic axial spondyloarthritis (26, 27) .
In conclusion, our long-term study in a setting of clinical practice showed that inflammatory parameters (i.e. CRP, ESR) and disease duration represent important predictive variables to achieve PR with anti-TNFα treatment, irrespective of damage or sacroiliac joint involvement. 
